Literature DB >> 274174

Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.

G J Lauzon, J H Paran, A R Paterson.   

Abstract

When incubated with 1-beta-D-arabinofuranosylcytosine (ara-C), RPMI 6410 cells formed a hitherto unrecognized ara-C metabolite, 1-beta-D-arabinofuranosylcytosine diphosphate choline. This compound was characterized by (a) chromatographic behavior, (b) chemical and enzymatic hydrolysis, (c) phosphorus content, and (d) incorporation of [5-3H]ara-C and [methyl-14C]choline. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline by RPMI 6410 cells was enhanced in the presence of 3-deazauridine (DU) and was preceded by that of 1-beta-D-arabinofuranosylcytosine triphosphate. The antiproliferative effects of ara-C and DU toward RPMI 6410 cells were potentiated when the agents were present together. The anabolism of ara-C during a 24-hr interval of culture was markedly enhanced by the presence of DU; cellular concentrations of 1-beta-D-arabinofuranosylcytosine triphosphate and 1-beta-D-arabinofuranosylcytosine diphosphate choline were 5- and 15-fold higher than those in the absence of DU. This enhancement appears to be the basis of the potentiation of cytotoxicity resulting from combination of the agents. Pretreatment of RPMI 6410 cells with DU resulted in enhanced rates of cellular uptake of ara-C. ara-C uptake under these circumstances was blocked by the inhibitor of nucleoside transport, nitrobenzylthioinosine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 274174

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

2.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.

Authors:  J A Streifel; S B Howell
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

4.  Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.

Authors:  J S Wiley; J Taupin; G P Jamieson; M Snook; W H Sawyer; L R Finch
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

5.  Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.

Authors:  J S Wiley; S P Jones; W H Sawyer; A R Paterson
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

6.  Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.

Authors:  J L Yang; E H Cheng; R L Capizzi; Y C Cheng; T Kute
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

7.  The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia.

Authors:  R L Capizzi; C White
Journal:  Yale J Biol Med       Date:  1988 Jan-Feb

8.  Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

Authors:  T E Bapiro; K K Frese; A Courtin; J L Bramhall; B Madhu; N Cook; A Neesse; J R Griffiths; D A Tuveson; D I Jodrell; F M Richards
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.